The Markets Are Open: Eli Lilly Co. (NYSE:LLY)

Home » Post Category Eli Lilly Co. (NYSE:LLY)

Showing posts with label Eli Lilly Co. (NYSE:LLY). Show all posts

Eli Lilly & Co. (NYSE:LLY) Extends Rally on positive studies of new cancer drug, Hit New Highs

Shares in Eli Lilly & Co.(NYSE:LLY) rose more than 4 percent on Monday and added further 1.50% to $53.30 this morning after the company said that trials on a drug for treating stomach cancer had met the goals of improved patient survival and progression-free survival in a late-stage study that compared it to a dummy treatment.

The company said in a statement that the most common side effects for the medicine, ramucirumab, were high blood pressure, diarrhoea and headache.

The drug was tested in patients with gastric cancer that had spread to other parts of the body.

Gastric cancer affects the stomach lining and often goes undetected while developing slowly, Lilly said. Gastroesophageal junction cancer forms where the oesophagus connects to the stomach.

According to Leerink Swann analyst Seamus Fernandez who has upgraded the stock to Buy from Hold, the drug has an 80 percent chance of approval as a second line of treatment. The drug is in the final stage of testing for regulatory approval by the US FDA.

The drug has the potential to generate revenues of $600 million.

Shares in Eli Lilly rose 4.12 percent to close at $52.53. The shares have risen 37 percent in the past one year. Moreover, this morning the stock made a new high at $53.88.

The company said it planned the release details of the study at an upcoming scientific meeting. It is also studying the drug in combination with "the chemotherapy drug paclitaxel in a separate, late-stage trial. It also is examining the drug in late-stage testing as a potential treatment for breast, colorectal and lung cancers."

You have read this article Eli Lilly Co. (NYSE:LLY) / LLY / NYSE:LLY with the title Eli Lilly Co. (NYSE:LLY). You can bookmark this page URL http://calliecountrychatter.blogspot.com/2012/10/eli-lilly-co-nyselly-extends-rally-on.html. Thanks!

Eli Lilly & Co. (NYSE:LLY) might have hit upon a potential cancer cure

The pharmaceutical company based in Indianapolis, Eli Lilly & Co.(NYSE:LLY) has recently declared that they may have hit upon a long-term cure of stomach cancer, and that their recent tests have been successful, since they think that the medicine might ensure the increased rate of survival for the cancer patients, and might make the condition progression-free in they years to come, as well! They said that their medicine was compared to a placebo treatment which is given during the late stages of a certain clinical study.

The aftermath of this announcement led to the rapid climbing of the shares of the pharmaceutical company. The prices increased by three percent, and came to $51.97 after a $1.52 increment. This is the rate as it was during morning trading on Monday. Lilly says that the treatment, which has been named ramucirumab, has been studied extensively. They studied the effects of their treatment with that of the placebo, on late-stage patients with gastroesophageal junction cancers or gastric cancers. While the latter tends to affect the lining of the stomach, the former tends to spread the cancer on the area which connects the esophagus to the stomach. They have said that the treatment gives out progression free survival, which is the estimate before a disease spreads, or the time before the person in the study passes away.

Lilly will be revealing the details of their ground-breaking study soon, they said. It will most likely be revealed at a scientific meeting which is due to happen soon. They will also have to subject the treatment for drug-approval, for which they need to start talking to the regulators. The company spokeswoman said recently that the specifics will be revealed as soon as they are ready. The treatment and the findings are still at a very nascent stage, as of yet. The company is holding separate trials to measure the effect of the new drug with the chemo-drug paclitaxel. This trail too, will be a late-stage trial.

The company hit upon ramucirumab after their acquisition of ImClone Systems Inc. in 2008. Lilly is also hopeful of the effects the drug will have on other forms of cancer.

You have read this article Eli Lilly Co / Eli Lilly Co. (NYSE:LLY) / LLY / NYSE:LLY with the title Eli Lilly Co. (NYSE:LLY). You can bookmark this page URL http://calliecountrychatter.blogspot.com/2012/10/eli-lilly-co-nyselly-might-have-hit.html. Thanks!

Eli Lilly & Co. (NYSE:LLY) downgraded to Underperform

Eli Lilly & Co.(NYSE:LLY) has been downgraded to Underperform by Cown & Co, citing risks in the drug firm's ability to develop new treatments and a patent dispute over its cancer treatment Alimta.

The research firm said in a note that the drug firm's shares are trading much higher than what it actually should, considering the risks attached to its business.

Shares of the company have risen by more than fifth this year, most of the gains coming during August, when it released preliminary results from trials that showed that solanezumab, its drug to treat Alzheimer's slowed down the process of mental decline in patients suffering from a milder form of the disease.

Analyst Steve Scala said that "solanezumab accounted for much of the stock's recent run," but according to him the drug was not likely to be a success and it would fail.

He wrote that he did not believe in the existing data and said that it was not sufficient for regulatory approval, and Lilly will pass on conducting another large, expensive study for more data.

Scala lowered his rating on Lilly shares to "underperform" from "neutral." The new rating means he expects the stock to perform worse than the Standard & Poor's 500 index.

Shares in Eli Lilly fell 0.3 percent to $50.45, though it rose about 0.15 percent in after-hours trading.

Eli Lilly & Co. (NYSE:LLY) And Roche Drugs Selected For Alzheimer’s Prevention Trial

Experimental drugs to cure Alzheimer’s disease from Roche Holding AG and Eli Lilly & Co.(NYSE:LLY) have been chosen for a high-profile medical trial to test if it is possible to stop the disease from developing in at-risk patients.

Th trial is expected to begin sometime next year. It is going to enroll 160 patients internationally with inherited gene mutations that usually result in Alzheimer’s symptoms when they are in their 30s. Washington University said this while announcing the selection of drugs on Wednesday.

Studies over drugs over the past decade have tried and failed to slow progression of Alzheimer’s among patients, who are undergoing dementia. There is hope of some triumph in arresting symptoms in patients, who are so highly inclined to develop the ailment. It will show the way to stop Alzheimer’s in a much wider population.

A neurologist from Washington University of Medicine, Dr. Randall Bateman said that the team is going to work on three different drugs with three different means of action in order to find out the best method.

Bateman said over a telephonic interview that half the patients in the trial do not have any symptoms when the study had started. The rest will have very minor symptoms.

A neurologist at New York University Langone Medical Center, Dr. James Galvin said that such a prevention trial that involves people at high hereditary risk of Alzheimer’s disease would need comparatively few patients and could generate results within a few years.

Gavin said that every family has a genetic mutation with a definite age of inception of ailment, so people can start giving the drug a certain number of years before the predicted onset.

Around 5 million people in the US and 36 million internationally are believed to have Alzheimer’s, which happens to be a common type of dementia.

Eli Lilly & Co. (NYSE:LLY): Alzheimer Drug ‘Lilly’ Shows Some Positive Effect In Mild Disease

Eli Lilly & Co. (NYSE:LLY)’s Experimental drug ‘Lilly’ seems to help slow mental decline in individuals with mild Alzheimer’s disease.

Through combined results from two different studies of an experimental Alzheimer’s drug indicate that it may modestly slow mental degradation particularly in people with mild Alzheimer’s disease.

When taken separately, the studies on the drug, Eli Lilly’s solanezumab missed their major goals of appreciably slowing the mental ailment or improving activities of daily living. However, pooled result showed that there was 34% less mental decline in people with mild Alzheimer’s disease when compared to those undergoing fake treatment for 18 months.

Doctors called the results heartening, even though probably not good enough to win consent of the drug at the moment, without another study to verify that there is a strong benefit. Investors were more enthusiastic about the results driving Lilly’s stock up by nearly 5% on Monday and about 19% since the month of August, when the firm had described the results in general terms.

Comprehensive results were revealed for the first time on Monday at an American Neurological Association conference that was held in Boston.

CEO of the Alzheimer’s Association, Maria Carillo said that it is certainly not the home run that the organization wanted but it was encouraged by the outcomes. An Alzheimer’s expert at Brown University, Dr. Stephen Salloway agreed to it. He said that it is exciting to see that there are possibilities of clinical benefits. He also said that the drug is modest and may not be enough to make a difference in how well patients live.

The drug has failed to help patients in two late-stage researches the previous month. However, it did show signs of hitting its target and clearing deposits from the brain.

The Lilly drug appears to be safe and that is the benefit of it, according to the head of a memory ailments program at New York Presbyterian Hospital, Dr. Norman Relkin.

Shares of the company are down 2.60% to $50.47 after soaring 9% in the past two trading sessions and made multi year high of $53.55 in yesterday’s session.

Eli Lilly & Co. (NYSE:LLY) shares Hit Multi Year Highs on encouraging results for Alzheimer’s drug

Pharma major Eli Lilly & Co.(NYSE:LLY) has sown that use of its experimental Alzheimer's drug, Solanezumab, may modestly slow down mental declines, especially in those patients who have a milder form of the disease or are in the initial stages.

It required the combined results of two studies to arrive at this conclusion. Taken separately, studies on the drug show that it missed the main goals of slowing down the disease or improving activities.

But when the two results were combined there was a significant 4 percent less mental decline in mild Alzheimer's patients compared to those who were on a placebo treatment for 18 months.

After the results of the studies were made public at the annual meeting of the American Neurological Association, shares in Eli Lilly rose to four-year highs. The stock soared 5.3 percent to $50.78 on Monday taking its total gains to 19 percent since August when it had described the results in general terms.

“It’s certainly not the home run we all wanted, but we’re very encouraged by these results,” said Maria C. Carrillo, senior director of medical and scientific relations for the Alzheimer’s Association, which had no role in the research.

The drug Solanezumab, which is still under trials, aims to bind to and help clear the sticky deposits that clog patients’ brains.

The two studies each had about 1,000 patients, about two-thirds with mild disease and one-third with moderately severe Alzheimer’s, in 16 countries. Their average age was 75.

Eli Lilly said that it would soon be seeking to file the drug for FDA approval.

Shares of LLY surged 5.30% to $50.78 and made multi-year high of $50.94. Shares rose another 4.21% to $52.87 in early trade on Tuesday.

Eli Lilly & Co. (NYSE:LLY)’s Empagliflozin Drug Shows Promising Results in Trial Phase

Eli Lilly & Co.(NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals were testing a diabetes related drug for sometime, but they have recently announced that the data from two trials comprising their experimental diabetes treatment looked promising as the drug has indeed been successful in reducing blood pressure, which is a serious risk for diabetic patients as it can lead to various health complications.

Empagliflozin, as the drug is called, is part of a class of drugs called SGLT-2 inhibitors. They are capable of reducing blood glucose by operating independently of insulin action. Christophe Arbet-Engels, vice president of metabolic-clinical development and medical affairs at Boehringer stated that most of oral type 2 diabetes treatments that are presently available are based on actions of the hormone insulin to lower elevated blood glucose. The upcoming SGLT-2 inhibitor class blocks glucose re-absorption in the kidney, thereby eliminating glucose via urine.

The trials are being closely monitored to test the effectiveness and safety of the empagliflozin drug. It has been administered alone or along with metformin adult patients with type 2 diabetes. Data regarding the trials are recorded immediately. Three trials of their diabetes drug Tradjenta, which has already been approved, revealed that the drug reduces hemoglobin A1c in senior patients with type 2 diabetes. A1c is a standard measure to regulate blood sugar levels.

The Markets Are Open